España (Spain)

En Recordati Rare Diseases nos centramos en una minoría: los afectados por las enfermedades minoritarias. Creemos que todos y cada uno de los pacientes tienen derecho al acceso al mejor tratamiento posible. Los pacientes con enfermedades minoritarias son nuestra mayor prioridad. Nuestra planificación, nuestros pensamientos y nuestras acciones giran en torno a ellos.

 

Recordati entra en el sector de las enfermedades raras en 2007 a través de la adquisición de Orphan Europe, una empresa especializada en enfermedades raras, consolidando su compromiso con los medicamentos huérfanos. En Recordati Rare Diseases somos pioneros en Medicamentos Huérfanos, ofreciendo soluciones terapéuticas en España y Portugal para 27 enfermedades raras, algunas de ellas “ultra-raras”, mejorando la calidad de vida de los pacientes que las padecen.

 

Nuestro equipo en España está compuesto por profesionales altamente cualificados y comprometidos que colaboran estrechamente con médicos, investigadores y organizaciones de pacientes para ofrecer soluciones terapéuticas de vanguardia. Nos enorgullece nuestra dedicación al bienestar del paciente, asegurando que cada uno de ellos tenga acceso al mejor tratamiento posible. En Recordati Rare Diseases España trabajamos con pasión y determinación para mejorar el día a día de quienes enfrentan estas condiciones poco frecuentes, siempre poniendo al paciente en el centro de todo lo que hacemos.

 

Recordati Rare Diseases Spain S.L.U. Avanzando en enfermedades minoritarias.

Contacto

Recordati Rare Diseases Spain S.L.U.
Vía de las Dos Castillas, 33, 3º.
Ática-Edificio 7
28224 Pozuelo de Alarcón (Madrid) – Spain
Phone: +34 91 659 28 90
Fax: +34 91 659 15 89

Notificación de reacciones adversas

 

El programa de farmacovigilancia en Recordati Rare Diseases, persigue mejorar la atención al paciente y su seguridad en relación con el uso de nuestros medicamentos. Damos apoyo a los programas de salud pública proporcionando información fiable y equilibrada para la evaluación efectiva del perfil riesgo-beneficio de los medicamentos.

 

Empresas como Recordati Rare Diseases toman las medidas oportunas para obtener y recopilar todos los informes sobre sospechas de reacciones adversas asociadas con productos medicinales para uso humano. Para garantizar la seguridad continuada del paciente, las agencias normativas exigen a empresas como Recordati Rare Diseases que continúen estudiando las posibles reacciones adversas de nuestros productos antes y después de su aprobación.

 

Animamos a todos nuestros pacientes y a sus profesionales de atención sanitaria a comunicarnos cualquier posible reacción adversa escribiendo a:

Productos

ENDOCRINOLOGÍA

La información de productos está dirigida exclusivamente a profesionales sanitarios capacitados para prescribir en España, para lo que se requiere una formación especializada para su correcta interpretación.

 

Signifor®: Enlace a Ficha Técnica | Enlace Prospecto

Isturisa®: Enlace a Ficha Técnica | Enlace Prospecto

ONCOLOGÍA

La información de productos está dirigida exclusivamente a profesionales sanitarios capacitados para prescribir en España, para lo que se requiere una formación especializada para su correcta interpretación.

 

Fotivda®: Enlace a Ficha Técnica | Enlace Prospecto

▼Qarziba®: Enlace a Ficha Técnica | Enlace Prospecto

▼Sylvant®: Enlace a Ficha Técnica | Enlace Prospecto

Ledaga®: Enlace a Ficha Técnica | Enlace Prospecto

Caphosol®: IFU (instrucciones de uso de producto sanitario)

 

▼Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento

METABOLICAS Y OTROS

La información de productos está dirigida exclusivamente a profesionales sanitarios capacitados para prescribir en España, para lo que se requiere una formación especializada para su correcta interpretación.

 

Carbaglu®: Enlace a Ficha Técnica | Enlace Prospecto

Cystadane®: Enlace a Ficha Técnica | Enlace Prospecto

Cystagon®: Enlace a Ficha Técnica | Enlace Prospecto

Normosang®: Enlace a Ficha Técnica | Enlace Prospecto

Pedea®: Enlace a Ficha Técnica | Enlace Prospecto

▼Vedrop®: Enlace a Ficha Técnica | Enlace Prospecto

Wilzin®: Enlace a Ficha Técnica | Enlace Prospecto

DHA-Basic® (Alimento de Usos Médicos Especiales) 

Feed-PKU® (Alimento de Usos Médicos Especiales) 

 

▼Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento

Redes Sociales RRD España

   

 

 

 

ES-NPS-0173 Mar25

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK
Corrine Porry
HR Business Partner, Rare Diseases

Corinne Porry is the Human Resource Business Partner of the Rare Diseases BU and is passionate about leadership development, creating thriving work environments, and helping people and organizations reaching their full potential.


She joined Recordati Rare Diseases in 2019, as the HR Lead of the EMEA region, before evolving on the current role in April 2025.


Corinne is a seasoned HR leader with widespread experience in multinational organizations, particularly within fast-paced and innovation-driven environments. Previously to Recordati, she held key HR leadership roles at MSD Vaccines, Sanofi Pasteur-MSD JV and Electronic Arts in the Entertainment Industry, where she supported major transformations, organizational designs and talent strategies. Her leadership style is grounded in empowering people, aligning teams around a shared purpose, and building inclusive, high-performing cultures. She began her career in HR management roles across diverse sectors including Retail, Biopharmaceuticals and Technology.


She holds a degree in Business Management from Rennes University and a master in Human Resources Management from the IAE of Aix-en-Provence. She is also a certified Executive Coach (ICF).

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

This website contains information about products that may not be available in all countries or may be available under different trademarks, for different indications, or in different doses. If you are a US resident please click the button below.

Stay on Global Site
Go to US site

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO
Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.
ACEPTO
NO ACEPTO
Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.
ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Réseau des Associations Vouées aux Troubles Sanguins Rares

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Visit website

Lymphoma Canada (Lymphome Canada)

Lorsque l’on est confronté à un lymphome, on se sent vite dépassé. Nous sommes une communauté au sein de laquelle on peut parler de cette maladie qui est le cinquième cancer le plus fréquent au Canada.

Visiter le site web

Acromégalie Canada

Acromégalie Canada est un organisme à but non lucratif fondé en 2019 pour rassembler les Canadiens dont la vie a été touchée par l’acromégalie. Notre mission est de sensibiliser à l’acromégalie et au gigantisme par l’éducation tout en offrant un réseau de soutien aux patients et à leurs familles à travers le Canada.

Visiter le site web

Global Genes

Global Genes est une organisation éminente de lutte contre les maladies rares. Sa mission consiste à sensibiliser et éduquer la communauté mondiale ainsi qu’à établir des relations importantes et à fournir des ressources essentielles permettant aux défenseurs de cette cause de s’engager pour lutter contre leur maladie.

Visiter le site web

Regroupement Québécois des Maladies Orphelines

Par l’entremise de son Centre d’information et de ressources en maladies rares, la RQMO fournit des renseignements et du soutien aux professionnels de la santé, aux patients qui souffrent de maladies rares et orphelines ainsi qu’à leur famille.

Visiter le site web

Collège canadien de généticiens médicaux

Le CCMG est une organisation nationale canadienne qui aide ses membres, les gouvernements et le public en assurant la certification des personnes, en établissant des normes, en dispensant des formations, et en guidant la politique d’intérêt public.

Visiter le site web

National Urea Cycle Disorders Foundation (NUCDF, fondation nationale pour les troubles du cycle de l'urée)

La NUCDF (fondation nationale pour les troubles du cycle de l’urée) est dédiée à l’identification, le traitement et la guérison des troubles du cycle de l’urée.

Visiter le site web

Canadian Organization for Rare Disorders (CORD, organisation canadienne pour les maladies rares)

La CORD (organisation canadienne pour les maladies rares) est le réseau national canadien des organisations représentant toutes les personnes atteintes de maladies rares. La CORD s’engage en vue de promouvoir une politique et un système de santé qui répondent aux besoins des personnes atteintes de maladies rares.

Visiter le site web

The Garrod Association (l'association Garrod)

The Garrod Association (l’association Garrod) est un organisme canadien permanent à l’échelle nationale dédié à la coordination de la gestion de maladies métaboliques héréditaires.

Visiter le site web

Association canadienne de porphyrie

L’Association canadienne de porphyrie s’engage à promouvoir la santé en permettant aux personnes atteintes de porphyrie d’avoir accès à un service de conseil et à des informations pertinentes ainsi qu’à des programmes de soutien de groupe.

Visiter le site web

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatirarediseases.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Network of Rare Blood Disorder Organizations​

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Visit website

Lymphoma Canada

Dealing with lymphoma can be overwhelming. We are community that helps people talk about and cope with the fifth most common cancer in Canada.

Visit Website

Acromegaly Canada

Acromegaly Canada is a not-for-profit established in 2019 to bring together Canadians whose lives have been touched by acromegaly. Our mission: to raise awareness of acromegaly and gigantism through education while providing a network of support for patients and their families across Canada.

Visit Website

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Regroupement Québécois des Maladies Orphelines

Through its Center for Information and Resources on Rare Diseases, RQMO provides information and support to health professionals and to patients with rare and orphan diseases and their families.

Visit Website

Canadian College of Medical Geneticists

CCMG is a national Canadian organization that serves its members, governments and the public by certifying individuals, establishing standards, providing education, and informing public policy.

Visit Website

National Urea Cycle Disorders Foundation

The NUCDF is dedicated to the identification, treatment and cure of urea cycle disorders.

Visit website

Canadian Organization for Rare Disorders

CORD is Canada’s national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders.
Visit Website

The Garrod Association

The Garrod Association is a permanent Canadian body at the national level for the coordination of the management of inherited metabolic disorders.
Visit Website

Global Genes

Global Genes is a leading rare disease advocacy organization. Their mission is to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for their disease.
Visit Website

Canadian Association for Porphyria

The Canadian Association for Porphyria is dedicated to promoting health by providing individuals with porphyria access to related counselling, information, and group support programs.
Visit Website

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK
Elisabeth Bergmans
Head of Legal

Elisabeth holds a master degree in corporate and commercial law from the University of Maastricht, and has 17 years experience in the legal profession. She began her career at the Benelux law firm Loyens & Loeff in Amsterdam where she specialized in Private Equity, banking & finance and insolvency & restructuring.


Feeling the need to work closer to the business, Elisabeth then held different positions as Legal Counsel in various industries, such as pension fund investment management, sustainable energy and a private equity fund. In 2015 she joined Teva Pharmaceuticals’ European headquarters in Amsterdam, covering over the years different roles with growing responsibilities; in her last remit she was General Counsel EU Commercial, responsible for the European regional legal support of innovative medicines and commercial HQ activities. In 2021, Elisabeth moved to Milan and continued her activities from there.


In September 2024 she joined Recordati as Head of Legal RRD where she is responsible for the global legal support of the Rare Diseases B.U.

Davide Paganoni
Head of Oncology Franchise

Davide is a biologist with more than 20 years of experience in the Health Care business with a broad commercial experience that ranges from rare disease to OTC.  He joined RRD in 2022, with the acquisition of EUSA, where he used to be Head of Europe and Global Marketing. Prior to EUSA Davide had more experiences as General Manager for biotech and pharma companies as Amryt and Exeltis and before he gained a strong experience in rare disease and ultra-specialistic areas covering senior commercial roles in highly recognized companies like Alexion and Astra Zeneca.

Aziza Johnson
Head of Regulatory Affairs

Aziza Johnson holds a Bachelor of Pharmacy from the London School of Pharmacy and a master’s degree in law from the University of Leicester. She is also a certified Board member, having completed the ZHAW Board of Directors program.

 

Aziza has over 27 years of experience in regulatory affairs, clinical development, and scientific strategy across global pharmaceutical companies and regulatory agencies. She has worked on numerous drug development programs, from clinical trials to market launches, with expertise in orphan drug development, regulatory compliance, and pharmacovigilance. Her career spans leadership roles in both the public and private sectors, including positions at Pfizer and the Medicines and Healthcare products Regulatory Agency (MHRA), where she honed her skills in pharmaceutical regulation and drug approval processes. She also facilitated over 25 successful acquisitions, expanded into new markets, and secured numerous regulatory approvals across the FDA, EMA, MHRA, CFDA, TGA, ANVISA, and Health Canada.

 

In 2023, Aziza joined Recordati Rare Diseases as Head of Regulatory Affairs, where she oversees global regulatory affairs for treatments targeting rare diseases. She leads efforts to secure regulatory approvals across diverse markets, ensuring patients with unmet medical needs receive timely access to innovative therapies.

Francesco Palombi
Head of Finance

Francesco Palombi is an experienced finance executive with over 25 years of global experience across pharmaceuticals, energy, and luxury goods. He holds a Master’s degree in Business Management from the University Cattolica del Sacro Cuore of Milan.

 

He began his career in 1997 at Price Waterhouse and later moved to ENI S.p.A. and Snam Rete Gas, where he managed financial audits, reporting, and external financial statements. In 2005, he joined Roche, advancing to roles including Head of Accounting & Credit Management, Head of Finance & Manufacturing Controlling, and Head of Controlling & Business Analysis.

 

In 2015, he became CFO of Roche Thailand & New Markets, managing finance across multiple countries. He later served as Global Head of Finance for Supply Chain and Product Strategy at Roche, leading financial strategy for global supply chain and product management, before assuming his current role as Global Finance Head at Recordati Rare Diseases in 2022.

Juan-Carlos Gerena
Group Supply Chain Head

Juan Carlos Gerena is a results-driven executive with over 20 years of global experience in manufacturing, supply chain, and business development across diverse industries, including FMCG, pharmaceuticals (branded and generics), and commodities. He has a proven track record of leading large-scale transformations, driving operational excellence, and managing complex end-to-end supply chains in multicultural and international environments.


Currently, as VP of Global Supply Chain at Recordati Group, Juan Carlos oversees the supply chain strategy for both Specialty Pharma and Rare Diseases divisions. Previously, he led global supply operations for renowned organizations like Sobi, Teva Pharmaceuticals, Galderma, Novartis, and Mylan, achieving major milestones such as scaling supply chains to support global expansion, integrating supply networks post-acquisition, and optimizing S&OP processes. His expertise spans strategic sourcing, logistics, CDMO management, pipeline scalability, and digital transformation.


A dynamic leader with a focus on delivering value and operational efficiency, he also played pivotal roles at Shell Oil Products Europe and Unilever, managing complex logistics optimization projects, refinery supply chains, and innovative process development initiatives.


Juan Carlos holds an MBA from the University of Houston and a Bachelor of Science in Industrial Engineering from the University of the Philippines. A skilled communicator, he is fluent in Spanish, English, Italian, and Filipino, with a working knowledge of German. His global mindset, technical expertise, and cultural adaptability make him an influential leader in driving sustainable business growth and supply chain resilience.

Gianni Paniale
Human Resources Director

Gianni holds a degree in Business Administration from Bocconi University in Milan and has built a versatile career spanning management consulting and the pharmaceutical industry.  His professional journey began in 1989 at Proudfoot, a management consulting firm specialising in productivity and quality improvements. Gianni took on progressively senior roles, eventually leading international projects across Italy, France, Germany, the UK, and the Czech Republic.


In 1997, he joined Recordati, initially responsible for the Organisation department, he later assumed leadership of human resources for the commercial organisation in Italy. In 2004, Gianni played a pivotal role in Recordati’s international expansion, leading HR efforts for acquisitions, start-ups and the consolidation of local affiliates.


In 2022, he was appointed Human Resources Director for the Rare Diseases business unit, where he oversaw HR strategies for this specialised and impactful division of the Group. His career reflects a deep commitment to fostering organisational growth and development on both a domestic and global scale.

Georg Thies
Head of Endocrinology Franchise

Georg Thies holds a diploma in Biology and has over 30 years of experience in the pharmaceutical industry.

 

His career in pharma started in 1984 with an apprenticeship at AMERSHAM BUCHLER. He later studied Biology at the GEORG-AUGUST UNIVERSITY in Göttingen and participated in the ERASMUS Program at the KING’S COLLEGE in London.

 

After 2,5 years of civil service, he continued his career at ROCHE in 1995, progressing from Key Account Manager to roles in National and International Marketing for Oncology products.

In 2002 he joined Amgen in Switzerland as International Brand Director for Oncology and Business Unit Head Oncology Switzerland. From 2008 onwards he worked as a Country Director for Sweden.

In 2011, Georg returned to Switzerland, gaining experience in Project- and New Product Planning. He was appointed European Brand Director Cardiovascular in 2012 and European Franchise Director General Medicine in 2014, overseeing Cardiology, Nephrology, Osteoporosis, and Inflammation.

In 2016, he joined SHIRE/TAKEDA, eventually becoming the Global Commercial Executive Director and later VP Global Program Lead in Endocrinology. He concluded his tenure at TAKEDA as Global Commercial Lead Gastrointestinal.

Since August 2022, Georg has been the VP RECORDATI Rare Disease Franchise Head Endocrinology.

Luca Setti
Corporate Portfolio Management Director

Luca Setti is the Corporate Portfolio Management Director at Recordati Rare Diseases, where he is responsible for the evaluation of business development opportunities, and the strategic guidance for life cycle management and pipeline projects.


Luca joined Recordati in July 2020 as Corporate Portfolio Manager, playing a pivotal role in the latest transactions performed by the company in the rare disease space, and in the management of pipeline projects.


Prior to joining Recordati, Luca worked for 10+ years in the business and corporate development departments of Alfasigma and Chiesi Farmaceutici, where he led the completion of multiple asset deals and licensing transactions.


Luca holds a Master’s Degree in Management Engineering from the Politecnico di Milano

Caring for the planet

A clean environment is essential for people’s well-being: the health of the planet and the health of people are closely connected. The air we breathe, the water we drink and the climate we live in all have an impact on our wellbeing. Focusing on people’s health and being sustainable also means prioritising environmental protection while behaving responsibly towards future generations.

 

This is why we ensure we conduct business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the demands of our stakeholders.

Caring for our communities

Contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely an obligation or professional duty for Recordati but a moral imperative.

 

We believe that caring for the communities in which we’re a part is essential to help them develop and grow, and to foster a sense of pride and belonging among our people.

Our Culture

The Recordati culture is built on the pillars of entrepreneurship, purpose and belonging; all have been part of our company since our beginnings in a small pharmacy in Northern Italy almost 100 years ago.

 

At the heart of our culture are our people, who are focused on always doing the right thing in the right way. We work together – across businesses, borders, time zones and national cultures – to support patients around the world in unlocking the full potential of life.

 

We give people the opportunity to develop themselves and bring their own unique ideas and perspectives to the table. Our culture is one where people can truly be the best versions of themselves, are safe to speak up and empowered to make decisions and experiment, learning as they go.

Diversity & Inclusion

Diversity is at the heart of our business and we do not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics.

 

We work hard to create a safe and inclusive work environment, respecting everyone’s right to physical and psychological integrity, as well as freedom of opinion and association. We know that we each of us has a role to play in the success of Recordati and each of us is rewarded for the unique contributions we make, regardless of who we are or where we come from.

Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is the Managing Director and General Manager for EMEA at Recordati Rare Diseases, where he oversees the company’s business operations across Europe, the Middle East, and North Africa. In this role, he is responsible for a broad range of functions, including Commercial, Medical Affairs, Marketing, and Market Access as well as key enabling areas such as Human Resources, Finance, Legal, Compliance to support the business’s growth and success.

 

Luigi joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. During his tenure, he played a pivotal role in driving the expansion of the company’s rare disease portfolio, leading efforts in business development, strategic marketing, and the management of pipeline projects.

 

Prior to joining Recordati, Luigi held senior positions in business and corporate development at Chiesi Farmaceutici and Menarini Group, where he successfully led numerous high-impact asset deals and transactions.

Luigi holds a degree in Economics from the University of Florence and a Master’s in Business Innovation from the prestigious Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region

Bruno Parenti is VP of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific, and Russia. He started opening new markets in 2012, spearheading the expansion of operations around the globe including the direct entry in Japan, China, South Korea, Australia, Brazil, Colombia, Mexico, and Argentina. In the last 2 years, he has successfully integrated the oncology portfolio in the Region, with new launches expanding the access to these life changing therapies to more and more patients.

 

From 2019 to 2022 he has held the additional role of Head of Global Endocrinology, establishing the new HQ in Basel, building from scratch a dedicated organization and coordinating the global launch of Isturisa and the re-launch of Signifor.

 

Prior to these positions, he spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is  responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site